The five-year rate of survival for pancreatic cancer is at 12% having the highest mortality rate of any major cancer.
Defence, an aptly-named biopharmaceutical company in Vancouver, B.C. recently announced through its June 2023 News Release that it has directed the Transbiotech Biotechnology Center to begin testing ARM, its anti-cancer therapy.
Cancer treatment vaccines are a type of immunotherapy that strengthens natural defenses and are designed for people who have cancer.
About Monoclonal Antibody Drugs
Monoclonal antibody drugs enlist the body’s defense against various diseases, including cancer. Accumtm Technology was developed by Defense in a novel approach that converts connective tissue cells into antigen-presenting cells which help the immune system attack solid tumors.
The vaccine was tested using enviro animals, melanoma, and solid T-cell lymphoma. It was found to have cured 80 to 100% of the treated animals with the tumors regressing completely.
Defence contacted Transbiotech Biotechnology asking them to take one step further and test the effectiveness of its ARM vaccine in animals who had pre-established pancreatic tumors. Transbiotech reported that the ARM vaccine was extremely effective against animal models.
Different animals from the same species (allogenic) will receive treatment together with an anti-PD-1 immune checkpoint inhibitor.
The CEO of Defense, Sebastien Plouffe, stated that the ARM vaccine study should be able to clearly show its potency as compared to the current, failed standard. He further stated that should the vaccine perform as expected, we would be witnessing the first step in delivering the next generation of vaccine antigens to target cells.